Cure8 research brief
The study suggests anti-TNF failure in Crohn's may be driven by pre-existing cytokine interaction networks and loss of regulatory feedback, which could help explain why some patients don't respond to TNF-blocking biologics and point to new targets or combination strategies.
Researchers studying IBD mechanisms, clinicians treating patients with anti-TNF biologics, and patients on biologic therapy interested in why treatment might fail.
This study analyzes single-cell data from Crohn's patients before and after anti-TNF therapy and reconstructs interacting cytokine networks that differ between responders and non-responders.
Non-responders had a unique pre-treatment inflamed network centred on IL17C and downstream inflammatory mediators, while responders retained IL10-associated regulatory circuits and acquired tissue-remodelling interactions after treatment.
The findings are presented as a mechanistic, systems-level hypothesis for why some patients fail anti-TNF therapy — namely, that compensatory cytokine networks (not just single cytokines) sustain inflammation independent of TNF.
The work is framed as a preprint/abstract-level report and uses network reconstruction and validation against randomized networks, plus confirmation in an independent cohort at the gene-set level.
Preprint / abstract-level report using single-cell RNA-seq and computational network methods. Findings are hypothesis-generating and need peer review and experimental/clinical validation before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
